2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2607

Favorable Changes in Lipid Profile with Additive DMARD Therapy in Rheumatoid Arthritis Patients Failing Methotrexate Monotherapy
Abstract Number: 892

FDG-PET CT Evaluation By Visual Grading Is Not Sufficiently Discriminative to Assess Disease Activity in Takayasu’s Arteritis Patients with ‘Persistent’ Disease
Abstract Number: 2043

Feasibility and Accuracy of Translating a Patient Safety Quality Measure into an Automated e-Measure
Abstract Number: 1281

Feasibility and Reliability of the Spondyloarthritis Research Consortium of Canada Sacroiliac Joint Inflammation Score for Children with Spondyloarthritis
Abstract Number: 1282

Feasibility and Reliability of the Spondyloarthritis Research Consortium of Canada Sacroiliac Joint Structural Score for Children with Spondyloarthritis
Abstract Number: 420

Feasibility of a Rheumatology Staff Protocol for Tobacco Cessation Counselling and Quit Line Electronic Referral
Abstract Number: 2890

Feasibility of Same Day Adipose Tissue Harvest, Cell Processing and Subcutaneous Delivery of Adipose Derived Regenerative Cells into Fingers of Scleroderma Patients within a Randomized Double Blind Clinical Trial
Abstract Number: 1369

Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM)
Abstract Number: 2948

Fecal Calprotectin Level Is Useful in Identifying Active Disease in Behçet’s Syndrome Patients with Gastrointestinal Involvement: A Controlled Study
Abstract Number: 1258

Female Gender Is Associated with a Poorer Response to TNF-Inhibitors in Ankylosing Spondylitis
Abstract Number: 2282

Ferritin Levels Are Associated with Urate and Gout – a Role for Iron Metabolism in Gout ?
Abstract Number: 1849

Fibroblast Growth Factor 9/ Fibroblast Growth Factor Receptor 3 Signaling Is Upstream of Several Profibrotic Pathways and Induces Fibroblast Activation and Tissue Fibrosis in SSc
Abstract Number: 48

Fibromyalgia Impact Is a Potential Mediator for the Associations of Self-Efficacy and Pain Catastrophizing with Physical Functioning in Persons with Fibromyalgia
Abstract Number: 1870

First Pilot Study of an Implantable Loop Recorder (ILR) in Systemic Sclerosis Detects Significant Cardiac Arrhythmias with CMR Abnormalities
Abstract Number: 490

First Report of Symptoms Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].